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ABSTRACT 
Objective: To study the effect of ethanolic extract of Glycyrrhiza glabra against streptozotocin and high-fat-diet-induced diabetes and 
hyperlipidemia. 
Methods: The present study was conducted on a 14 d model in which Glycyrrhiza glabra extract was given to streptozotocin (STZ; 50 mg/kg; i. p.) 
induced diabetic rats fed with high fat diet (HFD), and its protective effect has been studied. The antihyperlipidemic and antihyperglycemic effects 
have been evaluated on the basis of physical, biochemical as well as histomorphological parameters. 
Results: The Glycyrrhiza glabra extract pre-treated group showed a significant decrease in biochemical parameters like Total cholesterol (TC), 
Triglyceride (TG), High-density lipoprotein (HDL), Lactate dehydrogenase(LDH), Alanine transaminase (ALT) compared with D-HFD group 
(p<0.01). The pre-treated groups also showed significant protection in physical parameters as compared to D-HFD group (p<0.01) which was also 
confirmed by histopathological studies. All these results were compared and found to be similar with two standard drugs metformin (500 mg/kg) 
and atorvastatin (10 mg/Kg). 
Conclusion: This study concluded that alcoholic extract of Glycyrrhiza glabra (500 mg/kg) has significant antidiabetic and antihyperlipidemic 
potential against streptozotocin and high-fat diet induced diabetic hyperlipidemic rats comparable to the clinically used drugs.  
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INTRODUCTION 
Diabetes mellitus is a metabolic disorder that is characterized by 
chronic hyperglycemia (high blood sugar) resulting with 
carbohydrate, fat and protein metabolism disturbances. Diabetes 
mellitus can be classified into (type-1) diabetes also known as 
insulin-dependent diabetes mellitus (IDDM) and (type-2) diabetes 
which is known as non-insulin dependent diabetes mellitus 
(NIDDM). Diabetes mellitus is associated with an increased risk of 
coronary artery heart disease [1-3]. 
Heart failure is common in patients with uncontrolled diabetes mellitus, 
indicating that hyperglycemia may be responsible for this. Studies and 
clinical trials indicate that hyperglycemia is the main cause of 
complications associated with diabetes mellitus. One of the major 
complications of diabetes is the formation of glycosylated end products 
(AGE). These end products will react with other proteins to generate free 
radicals in diabetic patient’s hence increasing permeability and 
thickening of blood vessel walls with loss of elasticity. Elevated blood 
glucose can result in damage of blood vessels. Examples of chronic 
complications are diabetic retinopathy, coronary artery disease 
(atherosclerosis), renal failure, limb amputation and eventually 
premature death. Macrovascular disease leads to cardiovascular 
complications such as coronary artery disease (angina or myocardial 
infarction), ischemic stroke and muscle wasting. Diabetic foot may also 
result in skin ulcer and infection by gangrene [4-6]. 
Diabetes mellitus is associated with profound alterations in the 
plasma lipid and lipoprotein profile with an increased risk of 
premature atherosclerosis, coronary insufficiency, and myocardial 
infarction. One of the major pathogenesis of lipid metabolism 
disturbances in diabetes is the increased mobilization of fatty acids 
from adipose tissue and secondary elevation of free fatty acid level 
in the blood, leading to the production of ketone bodies in the liver. 
Numerous cardiovascular complications and ailments are related to 
a process called atherosclerosis. Atherosclerosis is a condition that 
develops when a substance called plaque builds up in the walls of 
the arteries. This buildup narrows the arteries, making it harder for 
blood to flow through. If a blood clot forms, it can stop the blood 
flow. Atherosclerosis can cause a heart attack or stroke [5-6]. 
Atherosclerosis results from a pathological state called hyperlipidemia, 
which is a heterogeneous group of disorders characterized by an excess 
of lipids in the bloodstream. These lipids include cholesterol, cholesterol 
esters, phospholipids, and triglycerides. Hyperlipidemia is caused due to 
high levels of serum cholesterol especially excess LDL-C and/or excess 
triglycerides. Hypercholesterolemia is generally asymptomatic. 
Hypertriglyceridemia is generally asymptomatic until triglyceride levels 
are sustained above 1000 mg/dL. Hyperlipidemia is a major modifiable 
risk factor for atherosclerosis and cardiovascular disease, including 
coronary heart disease [7-11]. 
Type 2 diabetics are most likely to become ill, disabled, or even suffer 
fatality due to cardiovascular complications, and for many patients, they 
are also dealing with the condition of hyperlipidemia, though very few 
are aware of it. According to a study in the Journal of the American 
Medical Association (1989), only about 25 % of non-Hispanic whites 
with diabetes are aware of their hyperlipidemia, and less than 10 % of 
those are receiving treatment. As is commonly the case with type 2 
diabetics, obesity remains a significant concern, and for those also 
suffering from hyperlipidemia, achieving weight loss becomes an even 
stronger necessity for the individual. Obese patients with diabetic 
hyperlipidemia are at a great risk for health complications from 
hypertension, health function, heart disease, and the risk of mortality, 
according to Quality of Life Research (1998). Proper exercise and fitness 
must be a part of management for patients, recommend researchers in 
Acta Diabetologica (2003), in order to control any type of metabolic 
syndrome including diabetic hyperlipidemia [11]. 
Glycyrrhiza glabra 
Glycyrrhiza glabra is a hard herb or undershrub from the family 
Leguminosae (class: dicotylidonae), attaining a height up to 6ft. 
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leaves multifoliate, imparipinnate, flowers in axillary spikes, 
papilionaceous, lavender to violet in colour, pods compressed, and 
containing reniform seeds. The dried, peeled or unpeeled 
underground stems and roots constitute the drug, known in the 
trade as Liquorice. Flowers in March and fruits in August. 
Glycyrrhiza glabra Linn is a hardy perennial shrub, attaining a height 
up to 2.5 m. The leaves are compound, imparipinnate, alternate, 
having 4-7 pairs of oblong, elliptical or lanceolate leaflets. The 
flowers are narrow, typically papilionaceous, borne in axillary 
spikes, lavender to violet in colour. The calyx is short, campanulate, 
with lanceolate tips and bearing glandular hairs. The fruit is a 
compressed legume or pod, up to 1.5 cm long, erect, glabrous, 
somewhat reticulately pitted, and usually contains 3-5 brown, 
reniform seeds. The taproot is approximately 1.5 cm long and 
subdivides into 3-5 subsidiary roots, about 1.25 cm long, from which 
the horizontal woody stolons arise. These may reach 8 m and when 
dried and cut, together with the root, constitute commercial 
liquorice. It may be found peeled or unpeeled. The pieces of root 
break with a fibrous fracture, revealing the yellowish interior with a 
characteristic odour and sweet taste [12-14]. 
India has a rich heritage of traditional medicine, and the traditional 
health care system have been flourishing for many centuries. 
Traditional medicine, defined by the WHO as "medical knowledge 
systems that developed over generations within various societies 
before the era of modern medicine, including the health practices, 
approaches, knowledge and beliefs incorporating plant, animal and 
mineral-based medicines, spiritual therapies, manual techniques and 
exercises, applied singularly or in combination to treat, diagnose and 
prevent illnesses or maintain well-being" is used globally and has 
rapidly growing economic importance. Traditional Medicines 
derived from medicinal plants are used by about 60 % of the world’s 
population. This review focuses on Indian Herbal drugs and plants 
used in the treatment of diabetes, especially in India. Though there 
are various approaches to reduce the ill effects of diabetes and its 
secondary complications, herbal formulations are preferred due to 
lesser side effects and low cost. A list of medicinal plants with 
proven antidiabetic and related beneficial effects and of herbal drugs 
used in the treatment of diabetes is compiled. These include, Annona 
squamosa, Artemisia pallens, Areca catechu, Bombax ceiba, Butea 
monosperma, Capparis deciduas, Caesalpinia bonducella, Coccinia indica, 
Emblica officinalis, Eugenia uniflora, Enicostema littorale, Ficus 
bengalenesis, Gymnema sylvestre, Momordica cymbalaria, Murraya 
koenigii, Musa sapientum, Phaseolus vulgaris, Punica granatum, Salacia 
reticulate, Swertia chirayita, Scoparia dulcis, Syzygium alternifolium, 
Terminalia belerica, Terminalia chebula, Tinospora crispa, Vinca rosea, 
Withania somnifera [15-17]. Hyperlipidemia is a disorder of lipid 
metabolism manifested by elevation of plasma concentrations of the 
various lipid and lipoprotein fractions, which is the key risk factor for 
cardiovascular disorders (CVD). Since synthetic drugs have been shown 
to have side effects, the clinical importance of the herbal drugs in the 
treatment of hyperlipidemia has received considerable attention in 
recent years. Capparis Deciduas F., Ricinus Communis L., and Zizyphus 
Jujuba L. are traditionally used as antihyperlipidemic drugs as per 
ayurvedic literature. Some plants are used in the treatment of 
hyperlipidemia given below Glycyrrhiza glabra, Garlic powder (Allicor), 
Black tea, Green tea, Licorice, Commiphora Mukul (guggul) [16]. 
AIM  
To study the effect of ethanolic extract of Glycyrrhiza glabra against 
streptozotocin and high fat diet induced diabeties and hyper 
lipidemia in rats. 
MATERIALS AND METHODS 
Animals 
Male sprague-sprague-dawley rats (l50-200g) were used for the study. 
They were housed five each in sanitized polypropylene cages containing 
paddy husk as bedding under standard laboratory conditions at room 
temperature (23  °C±2  °C) with 12 h light/dark cycle. The animals were 
randomized into experimental and control groups. They had free access 
to standard pellets as basal diet and water ad libidum. Ethical clearance 
was obtained from Institutional Animal Ethical Committee (IAEC, 
Proposal No. IU/Pharm/ M Pharm/IAEC/14/07) Faculty of pharmacy, 
Integral University, Lucknow. 
Collection, authentication of crude drug and preparation of 
plant extract 
Dried rhizomes of Glycyhhriza glabra were purchased from the local 
market of Lucknow. The drug was authenticated by a taxonomist of 
National Botanical Research Institute Lucknow. Reference no 
NBRI/CIF/409/2014. The rhizomes of the plant were dried in the 
laboratory at room temperature and powdered in a mixer grinder. 
The extract was prepared by extracting the powder in 95 % ethanol 
which was stirred magnetically at every 4h at room temperature for 
72 h. The residue was removed by filtration, and it was once again 
extracted as above and filtered. The filtrate was evaporated to 
dryness at 40-50 °C under reduced pressure in a rotary evaporator 
(yield of ethanol extract was approximately 10 %). 
Chemicals 
Streptozotocin (STZ) 
Streptozotocin was freshly dissolved in the citrate buffer (0.05 
moles/litre) of pH 4.5 and administered with a dose of 45 mg/kg 
body weight intraperitoneally (Follansbee et al. 1997).  
Atorvastatin solution  
Standard atorvastatin was dissolved in 0.9 % normal saline, and the 
freshly prepared solution was used as a standard drug. 
Metformin solution 
Metformin tablets were powdered and dissolved in 0.9 % normal 
saline, and the freshly prepared solution was given to the animals 
according to dose. 
Formaldehyde solution 
10 % Formaldehyde was freshly prepared from formalin to preserve 
organs and tissues. 
Plant extract solution 
The dried plant extract was dissolved in 0.9 % normal saline & 
freshly prepared solution was given to animals according to dose. 
Experimental protocol  
Induction of diabetes Mellitus  
Rats were fasted for 24 h before the induction of diabetes by 
streptozotocin injection. The STZ was freshly dissolved in 0.2M 
sodium citrate buffer, pH4.5 and overnight fasted SD rats were 
administered with a single dose of STZ (50 mg/kg intraperitoneally). 
After 48 hr of STZ injection diabetes Mellitus was confirmed by 
testing blood sample collected from the tip of the tail using a blood 
glucometer. The rats with a fasting blood glucose level 250 mg/dL 
were considered diabetic and were used or further study [18]. 
Experimental design 
The animals were allocated into 7 different groups. The normal 
group (NC) served as non-diabetic control rats treated with saline 
instead of STZ. All other groups were treated with STZ and served as 
diabetic groups, which followed two dietary regimen i.e. one group 
received normal pellet diet (D-NPD), and all other groups were fed 
with high-fat diet. The composition of the high fat diet was according 
to the table given [18-20]. 
 
Table 1: Composition of high-fat diet 
Ingredients Quantity (g/100g) 
 Corn Flour 25 
 Milk Powder 15 
 Sucrose 15 
 Caesein 5 
 Egg Yolk 3 
 Lard 35 
 Cholesterol 1 
 Salt Mixture 1 
Mukeem et al. 




All animals were divided equally into 7 different groups (5 each). At 
the beginning of the study (on day 0), the body weights and fasting 
blood glucose levels were measured of all animals. The animals of 
Normal Control (NC) and Diabetic-Normal pellet diet (D-NPD) 
groups were fed with normal pellet diet (NPD), and all other groups 
were fed with HFD along with NPD. Food and water intake were 
monitored daily during the entire experimental period. The food 
efficiency ratio (FER) was calculated at the end of study (15 d). Final 
body weight of all animals was taken and then animals were 
sacrificed with a high dose of diethyl ether (overnight fasted). A 
blood sample was collected from retro-orbital plexes/cardiac 
puncher and was allowed to clot for 30 min at room temperature. 
The serum was separated by centrifugation at 3000 rpm at 30 °C for 
15 min and was used for estimations. The animal aorta was isolated 
and kept in formalin solution (10 %) for histopathological study. The 
liver and heart were also excised immediately, rinsed with ice-cold 
normal saline, blotted with filter paper, weighed and preserved in 10 
% formalin solution for histopathological examinations [18-21]. 
 
Table 2: Experimental protocol 
S. 
No. 





Normal control 5 Administered with Normal saline instead of Streptozotocin (STZ) and fed with Normal Pellet Diet 
(NPD) 
2. Diabetic-normal 
pellet diet (D-NPD) 
5 Rats were administered with single dose of Streptozotocin (STZ; 50 mg/kg i. p.) and fed with Normal 
Pellet Diet (NPD) throughout the study period (15 d) 
3. Diabetic-high fat diet 
(D-HFD) 
5 Rats were treated with single dose of Streptozotocin (STZ; 50 mg/kg i. p.) and fed with high fat diet 
(HFD) throughout the study period(15 d) 
4. G. glabra (250 mg/kg) 
 
5 Rats were treated with single dose of Streptozotocin (STZ; 50 mg/kg i. p.), fed with High-fat diet 
(HFD) and pre-treated with extract of G. glabra (250 mg/kg/day) throughout the study period (15 d)  
5. G. glabra (500 mg/kg) 
 
5 Rats were treated with single dose of Streptozotocin (STZ; 50 mg/kg i. p.), fed with High Fat Diet 
(HFD) and pre-treated with extract of G. glabra (500 mg/kg/day) throughout the study period (15 d) 
6. Metformin (0.5 
mg/kg) 
 
5 Rats were treated with single dose of Streptozotocin (STZ; 50 mg/kg i. p.), fed with High Fat Diet 
(HFD) and pre-treated with Metformin (0.5 mg/kg/day)  
throughout the study period (15 d) 
7. Atorvastatin (10 
mg/kg) 
5 Rats were treated with single dose of Streptozotocin (STZ; 50 mg/kg i. p.), fed with High Fat Diet 
(HFD) and pre-treated with Atorvastatin (10 mg/kg/day) throughout the study period (15 d) 
 
RESULTS AND DISCUSSION 
Blood glucose level 
 
Table 3 (A): Initial blood glucose level (mg/dl) 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 77 94 87 82 105 89 ± 4.88 
Diabetic control 98 102 79 87 109 95 ± 5.35 
Diabetic-High Fat Diet 89 104 96 92 101 96 ± 2.76 
Atorvastatin(10 mg/Kg) 94 89 69 72 101 85 ± 6.23 
Metformin (500mg/kg)  66 102 75 67 89 79 ± 6.90 
Glycyrrhiza glabra(250 mg/Kg) 91 82 103 79 79 86 ± 4.60 
Glycyrrhiza glabra(500 mg/Kg) 78 69 101 79 84 82 ± 5.26 
 
Table 3 (B): Final blood glucose level (mg/dl) 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 77 102 88 75 103 89 ± 5.41 
Diabetic control 170 250 240 235 285 236 ± 18.67 
Diabetic-High Fat Diet 190 270 288 290 275 262.6 ±18.44 
Atorvastatin(10 mg/Kg) 168 174 165 190 185 176.4 ± 4.82 
Metformin (500mg/kg)  110 107 101 99 102 103.8 ± 2.03 
Glycyrrhiza glabra(250 mg/Kg) 133 130 125 127 134 129.8 ± 1.71 
Glycyrrhiza glabra(500 mg/Kg) 125 119 114 121 129 121.6 ± 2.56 
Values are expressed as mean for 5 animals in each group. All values are expressed as mean ± SEM calculated by one way ANOVA followed by 
tukey’s test (n=5). *= p<0.01 when Diabetic control compared with Normal Control, and all treated groups compared with Diabetic high fat diet. # = 
p<0.05when Diabetic high fat diet compared with Diabetic control. 
 
Table 4(A): Initial body weight (g) 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 209 210 210 211 211 210.2± 0.34 
Diabetic control 198 195 196 197 200 197.2 ± 0.83 
Diabetic-High Fat Diet 248 250 250 252 249 249.8 ± 0.67 
Atorvastatin(10 mg/Kg) 172 175.5 174 175 175 174.3 ± 0.62 
Metformin (500mg/kg)  200 200 200.5 200 200 202.1 ± 1.97 
Glycyrrhiza glabra(250 mg/Kg) 180 170 175 179 174 175.6 ± 1.8 
Glycyrrhiza glabra(500 mg/Kg) 250 249 245 250 248 248.4 ± 1.92 
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Table 4 (B): Final body weight (g) 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 225 220 228 226 222 224.2±1.42  
Diabetic control 160 175 200 185 180 180 ±6.51  
Diabetic-High Fat Diet 280 275 265 278 267 273 ±2.98  
Atorvastatin(10 mg/Kg) 184 185 182 187 186 184.8 ±0.86  
Metformin (500mg/kg)  212 215 220 218 210 215 ±1.84  
Glycyrrhiza glabra(250 mg/Kg) 265 255 249 269 250 257.6 ±1.77  
Glycyrrhiza glabra(500 mg/Kg) 240 243 247 239 245 242.4±1.14  
All values are expressed as mean ± SEM calculated by one way ANOVA followed by tukey’s t-test (n=5). *= p<0.01 when Diabetic control compared 
with Normal control, Diabetic high fat diet compared with Diabetic control and Glycyrrhiza glabra (250mg/kg), Glycyrrhiza glabra (500mg/kg)  
groups compared with D-HFD. #=p<0.05when Metformin, Atorvastatin compared with Diabetic high fat diet. 
 
Table 5: Total food intake 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 28 24 27 22 25 87.6±5.32  
Diabetic control 53 55 59 53 51 164.2 ±4.72  
Diabetic-High Fat Diet 75 81 77 71 83 212.6 ±9.65 
Atorvastatin(10 mg/Kg) 77 85 79 76 85 174.6 ±4.00  
Metformin (500mg/kg)  33 39 32 39 31 207.2 ±7.61  
Glycyrrhiza glabra(250 mg/Kg) 56 59 60 56 31 176 ±4.30  
Glycyrrhiza glabra(500 mg/Kg) 47 50 49 45 44 174.6±6.83  
 
Table 6: Food efficiency ratio 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 0.57 0.46 0.66 0.68 0.44 0.562±0.049  
Diabetic control -0.71 -0.36 -0.2 -0.22 0.39 -0.376 ±0.091  
Diabetic-High Fat Diet 0.42 0.31 0.19 0.36 0.21 0.298 ±0.043  
Atorvastatin(10 mg/Kg) 0.15 0.11 0.10 0.15 0.13 0.128 ±0.010  
Metformin (500mg/kg)  0.36 0.38 0.61 0.46 0.32 0.42 ±0.05  
Glycyrrhiza glabra(250 mg/Kg) 1.35 1.44 1.23 1.69 2.45 1.63 ±0.021  
Glycyrrhiza glabra(500 mg/Kg) -0.21 -0.12 -0.04 -0.24 -0.06 -0.134±0.039  
All values are expressed as mean ± SEM calculated by one way ANOVA followed by tukey’s t-test (n=5). *= p<0.01 when Diabetic control compared 
with Normal control, Diabetic high fat diet compared with Diabetic control and Glycyrrhiza glabra (250mg/kg), Glycyrrhiza glabra (500mg/kg)  
groups compared with D-HFD. #=p<0.05when Metformin, Atorvastatin compared with Diabetic high fat diet. 
 
Table 7: Liver weight (g) 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 9.12 9.52 9.33 9.01 9.07 9.21±0.09  
Diabetic control 10.27 10.89 10.5 10.7 10.2 10.51 ±0.12  
Diabetic-High Fat Diet 14.72 14.15 14.19 14.50 14.65 14.44 ±0.11  
Atorvastatin(10 mg/Kg) 12.21 12.01 12.09 12.34 12.07  12.14± 0.05 
Metformin (500mg/kg)  13.81 13.96 13.76 13.85 13.59 13.76 ±0.06  
Glycyrrhiza glabra(250 mg/Kg) 12.86 12.00 12.99 12.92 12.43 12.64 ±0.18  
Glycyrrhiza glabra(500 mg/Kg) 13.01 13.21 13.10 13.22 13.19 13.14±0.04  
All values are expressed as mean ± SEM calculated by one way ANOVA followed by tukey’s t-test (n=5). *= p<0.01 when Diabetic control compared 
with Normal control, Diabetic high fat diet compared with Diabetic control and Glycyrrhiza glabra (250mg/kg), Glycyrrhiza glabra (500mg/kg)  
groups compared with D-HFD. #=p<0.05when Metformin, Atorvastatin compared with Diabetic high fat diet. 
 
Table 8: Heart weight (g) 
Groups 1 2 3 4 5 Mean ± SEM 
Normal control 0.88 0.78 0.69 0.79 0.70 0.76±0.03  
Diabetic control 0.92 0.79 0.72 0.83 0.74 0.80 ±0.03  
Diabetic-High Fat Diet 1.12 0.99 0.97 1.00 0.98 1.01 ±0.02  
Atorvastatin(10 mg/Kg) 0.89 0.88 0.79 0.83 0.77 0.83 ±0.02  
Metformin (500mg/kg)  0.94 0.91 0.93 0.95 0.90 0.92 ±0.009  
Glycyrrhiza glabra(250 mg/Kg) 1.10 0.97 0.95 1.01 0.97 1.00 ±0.02  
Glycyrrhiza glabra(500 mg/Kg) 0.94 0.96 0.95 0.89 0.93 0.93± 0.01 
All values are expressed as mean ± SEM calculated by one way ANOVA followed by tukey’s t-test (n=5). *= p<0.01 when Diabetic control compared 
with Normal control, Diabetic high fat diet compared with Diabetic control and Glycyrrhiza glabra (250mg/kg), Glycyrrhiza glabra (500mg/kg)  
groups compared with D-HFD. #=p<0.05when Metformin, Atorvastatin compared with Diabetic high fat diet. 
Mukeem et al. 










































































































































































































































































































































































































































Fig 1 (a-g) All values are expressed as mean ± SEM calculated by one way ANOVA followed by tukey’s t-test (n=5). *= p<0.01 when Diabetic 
control compared with Normal control, Diabetic high fat diet compared with Diabetic control and Glycyrrhiza glabra (250mg/kg), Glycyrrhiza 
glabra (500mg/kg)  groups compared with D-HFD. #=p<0.05when Metformin, Atorvastatin compared with Diabetic high fat diet. 
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a) Total Cholestrol level (mg/dl)    
b) Triglyceride level (mg/dl)    
c) High density lipoproteins (mg/dl) 
d) Low density lipoproteins (mg/dl) 
e) Alanine transaminase level (mg/dl) 
f) Lactate dehydrogenase level (mg/dl) 
g) Atherogenic index
NC: Normal control                  G.glabra: Glycyrrhiza glabra 
D-NPD: Diabetic control         D-HFD: Diabetic-High Fat Diet 
 
Histopathological studies 
Histopathological studies were done from Puri pathology. The 
detailed report is enclosed as annexure (4). All photographs were 
taken on 40 x. Photomicrograph of the aorta of NC rats showed 
regularly arranged smooth muscle fibers with an outer lining of the 
flattened or cuboidal cell. In D-NPD, the photomicrograph of aorta 
showed thickened wall with the presence of lymphocytic infiltration 
and groups of cartilage cells surrounded by a rim of fibrous tissue. 
Two fragments of fatty tissue with lymphocytic infiltration. 
Photomicrograph of the aorta of DHFD showed flattened cell lining is 
intact. The outer wall of aorta showed remarkably thick layer of loose 
fibroconnective tissue lining with lymphocytic infiltration and 
presence of a large amount of fatty tissue. In atorvastatin-treated 
group the photomicrograph of aorta showed the wall of aorta was 
normal in thickness, but one thick fragment of fatty tissue was present. 
In metformin-treated group the photomicrograph of aorta showed the 
wall of aorta was normal in thickness and cellularity. The cells were 
regularly arranged with a fair number of cells showing vocuolation in 
their cytoplasm. A remarkably thick layer of fibro connective fatty 
tissue was seen on one side with lymphocytic infiltration.  
The photomicrographs of the aorta of G. glabra treated group 
showed that the wall was thin, cellularity was low, the cells were 
regularly arranged, flattened, cell lining was intact and fibro 
connective tissue on one side with fatty tissue was reduced in 
amount. No lymphocytic infiltration or columnar epithelial cell lining 
was seen in it. 
 
  
(a) Normal Control (b) Diabetic control 
  
(c) Diabetic-High Fat Diet (d) Atorvastatin 
  
(e) Metformin (f) Glycyrrhiza glabra 
Fig. 2: Histopathological studies of aorta of different group     
a.NC; b.D-NPD; c.D-HFD; d.Atorvastatin; e.Metformin; f.G.Glabra (500mg/kg) 
 
Hyperlipidemia is a common problem and leading cause of 
cardiovascular diseases related to atherosclerosis. The risk for all 
forms of cardiovascular diseases, including Coronary Heart Disease 
is increased substantially with diabetes mellitus. Furthermore, the 
Mukeem et al. 
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mortality rate in is muheart diserased patients who are suffering 
from diabetes is much higher than in nondiabetic subjects. India is 
known for its traditional medicinal systems—Ayurveda, Siddha, and 
Unani. Glycyrrhiza glabra is extensively reported to be used in both 
these systems of medicine for antioxidant, hypoglycemic and 
cardioprotective activities [7, 11-4]. 
Streptozotocin is a naturally occurring chemical that is particularly toxic 
to the insulin-producing beta cells of the pancreas in mammals. It is used 
in medical research to produce an animal model for Type 1 diabetes in a 
large dose as well as Type 2 diabetes with multiple low doses [20]. 
The present study was conducted on a 14 d model in which the effect 
of Glycyrrhiza glabra extract was observed on STZ induced diabetic rats 
that were fed with high fat diet (HFD). The study showed that STZ 
significantly elevates blood glucose level in D-HFD due to the presence of 
all potentiating factors, i.e., STZ and HFD. Glycyrrhiza glabra (500 mg/kg) 
showed very significant improvement against Streptozotocin-induced 
diabetes as blood glucose level was found to be less than the untreated 
D-HFD group [21]. 
The Food efficiency ratio (FER) is a parameter for assessment of 
induction of diabetes mellitus. Polyphagia (increased hunger) and 
polydipsia (increased thirst) which are symptoms of diabetes are 
assessed by FER [23, 24]. Glycyrrhiza glabra (500 mg/kg) and other 
pre-treated groups showed significant improvement in the food 
efficiency ratio (FER). 
The heart weight & liver weight are important physical parameters, 
which indicate the clinical symptoms of cardiac hypertrophy and 
non-alcoholic fatty liver disease (NAFLD) respectively [25], which 
have been significantly controlled by the given treatment of 
Glycyrrhiza glabra (500 mg/kg). 
Various high-fat diets with different composition were used to 
induce hyperlipidemia in experimental rats. In this study, HFD was 
used according to the method of Vijaya et. al [26] increased serum 
cholesterol and LDL-C level significantly. Studies showed that both 
LDL and VLDL have a positive role in atherogenesis [27,28]. The pre-
treated groups showed a significant decrease in these lipoproteins. 
HDL is considered to be beneficial lipoprotein as it has an inhibitory 
effect in the pathogenesis of atherosclerosis [29], pre-treated groups 
showed a significant elevation in HDL.  
The Atherogenic index is an important parameter to evaluate the 
plaque formation which is the leading cause of atherosclerosis & 
Ischaemic heart disease (IHD). HFD fed animals had very high 
atherogenic index compared to NPD group. Glycyrrhiza glabra 
extract (500 mg/kg) shows significant control in the Atherogenic 
index. Certain biochemical parameters like Alanine 
aminotransferase (ALT) and Lactate dehydrogenase (LDH) which 
were markers of tissue damage have also been analyzed, and the 
disease groups showed a significant elevation in these enzymatic 
levels and pre-treated groups showed a marked reduction in the 
same [22]. 
The protective effect of Glycyrrhiza glabra has also been confirmed 
by histopathological studies of the aorta which reveals the 
significant progression of atheromatous plaque in D-HFD challenged 
group whereas the pre-treated groups showed very less progression 
in the development of atherosclerosis. 
In the present study, Glycyrrhiza glabra extract (500 mg/kg) showed 
very significant antihyperlipidemic and antihyperglycemic activity 
against STZ and HFD induced diabetes and hyperlipidemia. All these 
results were compared and found to be similar with two clinically 
used drugs i.e. Metformin (500 mg/kg) and Atorvastatin (10 mg/kg).  
CONCLUSION 
This study concluded that high-fat diet al. ong with STZ induced 
diabetes is a very suitable, potent short-term model for evaluating 
the hypoglycemic and hypolipidemic effect in experimental animals. 
The parameters for evaluation of antihyperlipidemic and 
antihyperglycemic activities were the physical parameters, lipid 
profile and biochemical parameters along with histomorphological 
studies. The result of this study showed a significant reduction in 
physical parameters (body weight, heart weight, and liver weight) and 
lipid profile i. e total cholesterol, triglycerides, LDL-C, atherogenic 
index, and the two enzymatic markers, ALT and LDH. All these results 
were further confirmed by histopathological studies of aorta which 
showed a marked reduction in the development of atherosclerotic 
plaque in the pre-treated groups. The result of the present study 
concluded that Glycyrrhiza glabra has significant protection against 
STZ and HFD induced hyperlipidemia and diabetes which was 
compared to clinically used drugs, Atorvastatin, and Metformin. 
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